

Please type a plus sign (+) inside this box → ☐

PTO/SB-00A (03-00)

Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/APTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

5

**Complete if Known**

Application Number	10/685,031
Filing Date	October 14, 2003
First Named Inventor	Han et al
Group Art Unit	1624
Examiner Name	B. Kille
Attorney Docket Number	BMS-PH-7164(C)

**US PATENT DOCUMENTS**

Exam Init	Ref Dés	Document No.	Issue Date	Name	Class	Sub Class	FILING DATE If Appropriate
A.K.	1.	4,666,829	05/19/1987	Glenner et al.			
A.K.	2.	5,593,846	01/14/1997	Schenk et al.			
A.K.	3.	5,703,129	12/30/1997	Felsenstein et al.			

**FOREIGN PATENT DOCUMENTS**

		Country & Doc. No. (11)	Pub. Date (43)		Class	Sub Class	Translation Yes No
A.K.	4.	WO 95/22966	08/31/1995	Mathlowetz et al.			
A.K.	5.	WO 96/29313	09/26/1996	Wahl et al.			
A.K.	6.	EP0652009	05/10/1995	Dovey et al.			

**OTHER ART**

(including Author, Title, Date, Pertinent Pages, Publication, Etc.)

A.K.	7.	Ballestri et al., <i>J. Org. Chem</i> 56, p. 678 (1991)
	8.	C. J. Barnett et al., <i>Tetrahedron Lett.</i> 1997, 38 (5), p. 735.
	9.	Barton and McCarobie, <i>J. Chem. Soc. Perkin Trans. 1</i> , p. 1574 (1975).
	10.	Barton and Motherwell, <i>Pure &amp; Appl. Chem.</i> 53, p.15 (1981)
	11.	Bock et al., <i>J. Org. Chem</i> 1987, 52, pp. 3232-3239
	12.	Bock et al., <i>J. Med. Chem.</i> 1993, 36, pp.4276-4292.
	13.	Brown et al., <i>Tetrahedron Letters</i> , 1971, 8, pp. 667-670
	14.	F. A. Carey and R. J. Sundberg, "Advanced Organic Chemistry, Part A," <i>New York: Plenum Press</i> , 1990, pp. 304-305, 342-347, 475-479, 695-698
	15.	A. R. Chamberlin, <i>Chem. Rev.</i> 1997, 97, pp. 2243-2266
	16.	M. T. Crimmins et al., <i>J. Am. Chem Soc.</i> 1997, 119, pp. 7883-7884
	17.	<i>Chem. Rev.</i> 1992, 92, p. 919
	18.	D. A. Evans et al., <i>J. Am. Chem. Soc.</i> 1990, 112, p., " " 8215
	19.	D. A. Evans et al., <i>Org. Synth</i> 1990, 68, p.83-90

Please type a plus sign (+) inside this box → ☐

PTO/SB-01A (03-00)

Approved for use through 10/31/2002. OMB 0551-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

5

## Complete if Known

Application Number	10/685,031
Filing Date	October 14, 2003
First Named Inventor	Han et al
Group Art Unit	1624
Examiner Name	B. Kifle
Attorney Docket Number	BMS-PH-7164(C)

## OTHER ART

(including Author, Title, Date, Pertinent Pages, Publication, Etc.)

20.	T.W.Green and Wuts, Propective Grups in organic Synthesis (Wiley 1991)
21.	Glenner and Wong, <i>Biochem. Biophys. Res. Commun.</i> 120; pp.885-890
22.	<i>J. Med. Chem</i> 1999, 42, pp. 3889-3898
23.	<i>J. Org. Chem.</i> 1986, 51, p. 2402
24.	M. M. Ponpipom and W. K. Hagman, <i>Tetrahedron</i> 1999, 55, p. 6749.
25.	Benner et al. <i>J. Am Chem. Soc.</i> 103, p. 993 (1981)
26.	Schummer and Hofle, <i>Syn. Lett.</i> 1990 (11) p.643-714
27.	"Remington's Pharmeceutical Sciences," 17th ed. Mack Publishing Company, Easton, PA, 1985, p.1418.
28.	D. J. Selkoe, "Cell Biology of the amyloid (beta)-protein precursor and the mechanism of Alzheimer's disease," <i>Annu. Rev. Cell. Biol.</i> , 1994, 10: pp 373-403
29.	R.G. Sherrill et al., <i>J. Org. Chem.</i> 1995, 60, pp.730-734
30.	D.A. Evans. <i>Aldrichimica Acta</i> 1982,15pp.23-32
31.	D. A. Walsh, <i>Synthesis</i> , September 1980, p.677
32.	T. Mukaiyama et al., <i>Org. React.</i> 1994, pp. 1-104
33.	S. Nozaki et al., <i>Bull. Chem. Soc. Jpn.</i> 1982, 55, pp. 2165-2168.
34.	I. Paterson et al., <i>Org. React.</i> 1997, 51, pp 1-200
35.	P.J.Reider et al. <i>J.Org.Chem</i> 1987,52 p955
36.	
37.	
38.	
39.	
40.	
41.	

Please type a plus sign (+) inside this box



+

PTO/SU08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 5

## Complete if Known

Application Number 10/685,031  
Filing Date October 14, 2003  
First Named Inventor Han et al  
Group Art Unit 1624  
Examiner Name B. Kifle  
Attorney Docket Number BMS-PH-7164(C)

## U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
B.K.		5263241		Bochis et al	2/1/1994	
		5389631		Claremon	2/14/1995	
		5550126		Horwell et al	8/27/1996	
		5532359		Marsters et al	7/2/1996	
		5578629		Ciccarone et al	11/26/1996	
		5595990		Baldwin et al	1/21/1997	
		5602145		Samanen	2/11/1997	
		5618812		Pineiro et al	4/8/1997	
		5633251		Claremon et al	5/27/1997	
		5672596		Wyvrat et al	9/30/1997	
		5710153		Ohmoto et al	1/20/1998	
		5710171		Dinsmore et al	1/20/1998	
		5756528		Anthony et al	5/26/1998	
		5763437		Sato et al	6/9/1998	
		5817658		Siegel et al	10/6/1998	
		5852010		Graham et al	12/22/1998	
		5856326		Anthony et al	1/5/1999	
		5859012		Dinsmore et al	4/6/1999	
		5869682		DeSolms	2/9/1999	
		5872135		DeSolms	2/16/1999	
		5885995		Dinsmore	3/23/1999	
		5891889		Anthony et al	4/6/1999	
		5905077		Jungheim et al	5/18/1999	
		5919785		Dinsmore et al	7/6/1999	
		5936089		Carpino et al	8/10/1999	
		5965578		Graham et al	10/12/1999	

## FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Figures Appear	T <sub>2</sub>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
B.K.		WO	9828268		Athena Neurosciences Inc.	7/2/1998		
B.K.		WO	9822493		Athena Neurosciences Inc.	5/28/1998		

Examiner  
Signature

*Burch Kifle*

Date Considered

10/26/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Please type a plus sign (+) inside this box → +

PTO/SB/00A (08-00)

Approved for use through 10/31/2002. OMB 0551-0031  
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 5

### Complete If Known

Application Number	10/685,031
Filing Date	October 14, 2003
First Named Inventor	Han et al
Group Art Unit	1624
Examiner Name	B. Kifle
Attorney Docket Number	BMS-PH-7164(C)

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sub>e</sub>
		Office <sup>2</sup>	Number <sup>3</sup>	Kind Code <sup>4</sup> (if known)				
B.K.		WO	9837079		Berlex Laboratories Inc.	8/27/1998		
		WO	9858915		Boehringer Mannheim GMBH	12/30/1998		
		WO	9918951		Bristol-Myers Squibb Co.	4/22/1999		
		WO	9903826		British Biotech Pharmaceuticals Ltd.	1/28/1999		
		WO	9719053		British Biotech Pharmaceuticals Ltd.	5/29/1997		
		WO	9633165		British Biotech Pharmaceuticals Ltd.	10/24/1996		
		WO	9816523		COR Therapeutics Inc.	4/23/1998		
		WO	9907730		COR Therapeutics Inc.	2/18/1999		
		WO	9907731		COR Therapeutics Inc.	2/18/1999		
		WO	0038618		DuPont Pharmaceuticals Co.	7/6/2000		
		WO	0007995		DuPont Pharmaceuticals Co.	2/17/2000		
		WO	9967221		Elan Pharmaceuticals Inc.	12/29/1999		
		WO	9967220		Elan Pharmaceuticals Inc.	12/29/1999		
		WO	9966934		Elan Pharmaceuticals Inc.	12/29/1999		
		WO	9967219		Elan Pharmaceuticals Inc.	12/29/1999		
		WO	9932453		Elan Pharmaceuticals Inc.	7/1/1999		
		EP	0842944		Hoechst Aktiengesellschaft	5/20/1998		
		WO	9919305		Krenitsky Pharmaceuticals Inc.	4/22/1999		
		WO	9403437		Merck Sharp & Dohme	2/17/1994		
		WO	9828980		Merck & Co. Inc.	7/9/1998		
		EP	0434360		Merck & Co. Inc.	6/26/1991		
		EP	0421802		Merck & Co. Inc.	4/10/1991		
		WO	9736877		Merck & Co. Inc.	10/9/1997		
		WO	9509633		Merck & Co. Inc.	4/13/1995		
		WO	9736879		Merck & Co. Inc.	10/9/1997		
		WO	9917777		Merck & Co. Inc.	4/15/1999		
		WO	9405834		Merck & Co. Inc.	3/17/1994		
		WO	9639137		Merck & Co. Inc.	12/12/1996		
		WO	9844797		Merck & Co. Inc.	10/15/1998		
		WO	9745412		Merck & Co. Inc.	12/4/1997		
		WO	9822433		Athena Neurosciences Inc.	5/28/1998		
		WO	9822430		Athena Neurosciences Inc.	5/28/1998		
		WO	9822441		Athena Neurosciences Inc.	5/28/1998		
		DE	2934355		Bayer AG	3/12/1981		
Examiner Signature	<i>Burk Kifle</i>				Date Considered	10/26/04		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>1</sup>  
Unique citation designation number.<sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 5

### Complete If Known

Application Number	10/685,031
Filing Date	October 14, 2003
First Named Inventor	Han et al
Group Art Unit	1624
Examiner Name	B. Kifle
Attorney Docket Number	BMS-PH-7164(C)

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sub>2</sub>
		Office <sup>2</sup>	Number <sup>3</sup>	Kind Code <sup>4</sup> (if known)				
D.K.		WO	9727852		Merck & Co. Inc.	8/7/1997		
		WO	9900854		Merck & Co. Inc.	1/7/1999		
		WO	9745412		Merck & Co. Inc.	12/4/1997		
		WO	9738664		Merck & Co. Inc.	10/23/1997		
		WO	9736900		Merck & Co. Inc.	10/9/1997		
		WO	9827053		Ono Pharmaceutical Co.	6/25/1998		
		WO	9620918		Procter & Gamble Co.	7/11/1996		
		WO	9841510		Shionogi & Co. Inc.	9/24/1998		
		WO	9414776		Smithkline Beecham Corp.	7/7/1994		
		WO	9618602		Smithkline Beecham Corp.	6/20/1996		
		WO	9617833		Smithkline Beecham Corp.	6/13/1996		
		WO	9216524		Merck&Co.Inc	10/1/1992		
		WO	9535308		Vertex Pharmaceuticals Inc	12/28/1995		
		WO	9514471		Merck&Co.Inc	6/1/1995		

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
D.K.		Dingwall; J. Clinical Invest., 108, Nov. 2001, 1243-1246	
		Selkoe; J. Alzheimer's Disease, 3, 2001, p. 75-81	
		Tanzi and Parson, "Decoding Darkness, The Search for the Genetic Causes of Alzheimer's Disease", Perseus Publishing, 2000, pages xvii-xviii	
		Olson et al., Current Opinion in Drug Discovery and Development, 4, 2001, p. 390-401	
		P. J. Maurer et al, "Total synthesis of a mycobactin; mycobactin S2" Journal of the American Chemical Society, Vol. 105, no. 2, 1983, pages 240-245	
		Evans B.E.et al, Methods fro Drug Discovery: Development of Potent, selective,orally Effective Cholecystokinin Antagonists"Journal of Medicinal Chemistry, American Chemical Society, Vol.31,no.12,1988,pp 2235-2246	
		M. Adamczeski et al, "Novel sponge-derived amino acids, Journal of the American Chemical Society, Vo. 111, no 2, 1989, pages 647-654.	

Examiner  
Signature

*Burch Kifle*

Date Considered

10/26/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231